- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00120874
Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training
Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Presently some 4.5 million people are afflicted with Alzheimer's disease in the United States. At present pharmacologic treatment, although beneficial, is not curative. Certain nonpharmacologic treatments have assisted caregivers of AD patients by reducing their stress and burden, and others have aided patients, by improving their mood and physical functioning. Comprehensive, individualized approaches to improving Alzheimer's patients' symptomatology and caregiver stress and burden have not been systematically investigated in Alzheimer's patient care. This study seeks to train and counsel caregivers as well as develop an individualized, comprehensive management program that will seek to enhance the functioning of each patient participant.
Patients are randomly placed into one of two groups. Both groups receive memantine and comprehensive evaluations at baseline, 4, 12,28 and 52 weeks. Additionally, group 1 receives an individualized management program, which consists of home visits to get the patient exercising, doing enjoyable activities and cognitive stimulation, educational sessions for caregivers on coping with difficult situations and a caregiver support group to help with questions and emotional concerns.
Type d'étude
Inscription (Réel)
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
New York
-
New York, New York, États-Unis, 10016
- Fisher Alzheimer's Program, New York University School of Medicine
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients, 50 years of age or greater, residing in the community
- Presence of a family and/or professional caregiver willing and able to participate in all aspects of this study
- A diagnosis of probable Alzheimer's disease by Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) and NINCDS-ADRDA (McKhann,et al., Neurology,1984;34: 939-944) criteria
- A CT or MRI brain scan and medical work up compatible with the DSM-IV and NINCDS-ADRDA diagnostic criteria for Alzheimer's disease
- Mini-Mental State Examination scores of 3-14
- Global Deterioration Scale stages of 5 or 6
- A stage of 6a or greater on the Functional Assessment Staging instrument signifying the presence of dementia deficits in the ability to perform one or more basic activities of daily living
Exclusion Criteria:
- Non-English speaking patients and/or caregivers
- Subjects with a diagnosis of dementia due to conditions other than Alzheimer's disease.
- Subjects with a diagnosis of vascular dementia or a score greater than 4 on the modified Hachinski Ischemic Rating scale
- Patients with a major depressive disorder
- Patients with clinically significant laboratory abnormalities
- Patients receiving investigational pharmacologic agents
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Group 1
Individualized Management including caregiver training and Memantine
|
Individualized management program: consists of home visits to get the patient exercising, doing enjoyable activities and cognitive stimulation, educational sessions for caregivers on coping with difficult situations and a caregiver support group to help with questions and emotional concerns.
Autres noms:
Patients receive 10 milligrams of memantine twice daily.
Autres noms:
|
Comparateur actif: Group 2
Only Memantine
|
Patients receive 10 milligrams of memantine twice daily.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Change From Baseline in Clinician Interview-Based Assessment of Change Plus Caregiver Input (CIBIC-Plus) Global Score (New York Univeristy Version)
Délai: Baseline to 28 weeks
|
CIBIC-Plus is measured in units on a scale ranging from 1 to 7, where 1 is markedly improved, 4 is unchanged, and 7 is markedly worse
|
Baseline to 28 weeks
|
Change From Baseline in Clinician Interview-Based Assessment of Change Plus Caregiver Input (CIBIC-Plus) Global Score (New York Univeristy Version)
Délai: Baseline to 52 weeks
|
CIBIC-Plus is measured in units on a scale ranging from 1 to 7, where 1 is markedly improved, 4 is unchanged, and 7 is markedly worse
|
Baseline to 52 weeks
|
Change From Baseline of The Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory Modified for Severe Dementia Abbreviated Version (ADCS-ADLsev-abv)
Délai: Baseline to 28 weeks
|
The ADCS-ADLsev-abv is a structured questionnaire where each item consists of a series of hierarchical questions designed to determine a patient's ability to perform the activities of daily living as assessed by the caregiver.
Possible scores range from 0 to 39, where a higher score is indicative of greater capacities.
|
Baseline to 28 weeks
|
Change From Baseline of The Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory Modified for Severe Dementia Abbreviated Version (ADCS-ADLsev-abv)
Délai: Baseline to 52 weeks
|
The ADCS-ADLsev-abv is a structured questionnaire where each item consists of a series of hierarchical questions designed to determine a patient's ability to perform the activities of daily living as assessed by the caregiver.
Possible scores range from 0 to 39, where a higher score is indicative of greater capacities.
|
Baseline to 52 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Change From Baseline of the Severe Impairment Battery (SIB)
Délai: Baseline to 28 weeks
|
The SIB evaluates cognitive performance.
It is a 51 item scale which assesses social interaction, memory, language, orientation, attention, praxis, visuospacial ability and construction.
Scores range from 0 (greatest impairment) to 100 (least impairment).
|
Baseline to 28 weeks
|
Change From Baseline of the Severe Impairment Battery (SIB)
Délai: Baseline to 52 weeks
|
The SIB evaluates cognitive performance.
It is a 51 item scale which assesses social interaction, memory, language, orientation, attention, praxis, visuospacial ability and construction.
Scores range from 0 (greatest impairment) to 100 (least impairment).
|
Baseline to 52 weeks
|
Change From Baseline of the Mini-Mental State Examination (MMSE)
Délai: Baseline to 28 weeks
|
The MMSE is a graded on a 30 point scale that measures cognitive functioning.
A lower score indicates a higher level of impairment.
Complete scale range is -no cognitive impairment=24-30; mild cognitive impairment=18-23; severe cognitive impairment=0-17.
|
Baseline to 28 weeks
|
Change From Baseline of the Mini-Mental State Examination (MMSE)
Délai: Baseline to 52 weeks
|
The MMSE is a graded on a 30 point scale that measures cognitive functioning.
A lower score indicates a higher level of impairment.
Complete scale range is -no cognitive impairment=24-30; mild cognitive impairment=18-23; severe cognitive impairment=0-17.
|
Baseline to 52 weeks
|
Change From Baseline of the Functional Assessment Staging Disability Score (FAST-DS)
Délai: Baseline to 28 weeks
|
The FAST-DS assesses the magnitude of progressive functional deterioration by identifying characteristic progressive disabilities in participants with AD. Scores range from 1.0 (normal) to 7f (severe loss of ability, not even able to hold up head independently). Scores are made up of stages (1 through 7) and substages (from a to e for stage 6; from a to f for stage 7). The following scoring for substages is applied: 6a=6.0, 6b=6.2, 6c=6.4, 6d=6.6, 6e=6.8, 7a=7.0, 7b=7.2, 7c=7.4, 7d=7.6, 7e=7.8, 7f=8.0. Additionally, non-consecutive deficits are noted and scored as follows: full stage non-consecutive deficit=1.0, non-consecutive substage deficit=0.2. The overall FAST-DS score = (FAST Stage Score) + (Each Non-Consecutive FAST disability scored as described) |
Baseline to 28 weeks
|
Change From Baseline of the Functional Assessment Staging Disability Score (FAST-DS)
Délai: Baseline to 52 weeks
|
The FAST-DS assesses the magnitude of progressive functional deterioration by identifying characteristic progressive disabilities in participants with AD. Scores range from 1.0 (normal) to 7f (severe loss of ability, not even able to hold up head independently). Scores are made up of stages (1 through 7) and substages (from a to e for stage 6; from a to f for stage 7). The following scoring for substages is applied: 6a=6.0, 6b=6.2, 6c=6.4, 6d=6.6, 6e=6.8, 7a=7.0, 7b=7.2, 7c=7.4, 7d=7.6, 7e=7.8, 7f=8.0. Additionally, non-consecutive deficits are noted and scored as follows: full stage non-consecutive deficit=1.0, non-consecutive substage deficit=0.2. The overall FAST-DS score = (FAST Stage Score) + (Each Non-Consecutive FAST disability scored as described) |
Baseline to 52 weeks
|
Change From Baseline of The Behavioral Pathology in Alzheimer's Disease Frequency Weighted Severity Scale (BEHAVE-AD-FW)
Délai: Baseline to 28 weeks
|
The BEHAVE-AD-FW measures the frequency and severity of 25 behavioral symptoms with a total score and global rating.
Individual behavioral assessments are rated for severity (0=none to 3-most severe) and frequency (1=least frequent to 4=most frequent) which are then multiplied; scores for each of the 25 items are then summed.
Possible total scores range from 0 to 297.
The global rating is scored from 0 (not dangerous to patient, not troubling to caregiver) to 3 (dangerous to patient, highly troubling to caregiver).
Global rating was not analyzed for this study.
The higher the score the worse the outcome.
|
Baseline to 28 weeks
|
Change From Baseline of The Behavioral Pathology in Alzheimer's Disease Frequency Weighted Severity Scale (BEHAVE-AD-FW)
Délai: Baseline to 52 weeks
|
The BEHAVE-AD-FW measures the frequency and severity of 25 behavioral symptoms with a total score and global rating.
Individual behavioral assessments are rated for severity (0=none to 3-most severe) and frequency (1=least frequent to 4=most frequent) which are then multiplied; scores for each of the 25 items are then summed.
Possible total scores range from 0 to 297.
The global rating is scored from 0 (not dangerous to patient, not troubling to caregiver) to 3 (dangerous to patient, highly troubling to caregiver).
The higher the score the worse the outcome.
|
Baseline to 52 weeks
|
Change From Baseline of the Revised Memory and Behavior Problems Checklist (RMBPC): Frequency
Délai: Baseline to 28 weeks
|
The RMBPC is a 24 item rating scale of the frequency of memory and behavioral problems in the AD subject and of how upset or "bothered" their caregivers react.
Frequency is rated from 0 (least frequent) to 4 (most frequent) and caregiver reaction is rated from 0 (not at all) to 4 (extremely bothered or upset).
Higher scores indicate more frequent memory and behavioral problems in the subject with AD as well as a more upset or bothered caregiver.
Possible scores range from 0 to 96.
|
Baseline to 28 weeks
|
Change From Baseline of the Revised Memory and Behavior Problems Checklist (RMBPC): Caregiver Reaction
Délai: Baseline to 28 weeks
|
The RMBPC is a 24 item rating scale of the frequency of memory and behavioral problems in the AD subject and of how upset or "bothered" their caregivers react.
Frequency is rated from 0 (least frequent) to 4 (most frequent) and caregiver reaction is rated from 0 (not at all) to 4 (extremely bothered or upset).
Higher scores indicate more frequent memory and behavioral problems in the subject with AD as well as a more upset or bothered caregiver.
Possible scores range from 0 to 96.
|
Baseline to 28 weeks
|
Change From Baseline of the Revised Memory and Behavior Problems Checklist (RMBPC): Frequency
Délai: Baseline to 52 weeks
|
The RMBPC is a 24 item rating scale of the frequency of memory and behavioral problems in the AD subject and of how upset or "bothered" their caregivers react.
Frequency is rated from 0 (least frequent) to 4 (most frequent) and caregiver reaction is rated from 0 (not at all) to 4 (extremely bothered or upset).
Higher scores indicate more frequent memory and behavioral problems in the subject with AD as well as a more upset or bothered caregiver.
Possible scores range from 0 to 96.
|
Baseline to 52 weeks
|
Change From Baseline of the Revised Memory and Behavior Problems Checklist (RMBPC): Caregiver Reaction
Délai: Baseline to 52 weeks
|
The RMBPC is a 24 item rating scale of the frequency of memory and behavioral problems in the AD subject and of how upset or "bothered" their caregivers react.
Frequency is rated from 0 (least frequent) to 4 (most frequent) and caregiver reaction is rated from 0 (not at all) to 4 (extremely bothered or upset).
Higher scores indicate more frequent memory and behavioral problems in the subject with AD as well as a more upset or bothered caregiver.
Possible scores range from 0 to 96.
|
Baseline to 52 weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Barry Reisberg, M.D., NYU Langone Health
- Directeur d'études: Sunnie Kenowsky, D.V.M., NYU Langone Health
Publications et liens utiles
Publications générales
- Teri L, Gibbons LE, McCurry SM, Logsdon RG, Buchner DM, Barlow WE, Kukull WA, LaCroix AZ, McCormick W, Larson EB. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA. 2003 Oct 15;290(15):2015-22. doi: 10.1001/jama.290.15.2015.
- Reisberg B, Kenowsky S, Franssen EH, Auer SR, Souren LE. Towards a science of Alzheimer's disease management: a model based upon current knowledge of retrogenesis. Int Psychogeriatr. 1999 Mar;11(1):7-23. doi: 10.1017/s1041610299005554.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Les troubles mentaux
- Maladies du cerveau
- Maladies du système nerveux central
- Maladies du système nerveux
- Troubles neurocognitifs
- Maladies neurodégénératives
- Démence
- Tauopathies
- Maladie d'Alzheimer
- Effets physiologiques des médicaments
- Agents neurotransmetteurs
- Mécanismes moléculaires de l'action pharmacologique
- Antagonistes des acides aminés excitateurs
- Agents d'acides aminés excitateurs
- Agents dopaminergiques
- Agents antiparkinsoniens
- Agents anti-dyskinésie
- Mémantine
Autres numéros d'identification d'étude
- H12444-01 A
- NAM MD 18 (Autre subvention/numéro de financement: Forest Laboratories)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .